Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Nonsteroidal anti-inflammatory drugs and COX-2 inhibitors

4 evidence topics · 2 sources

Symptomatic role without evidence of flare-up prevention

“There is no definitive evidence that chronic treatment with COX-2 inhibitors or NSAIDs prevents or ameliorates flare-ups in FOP. However, COX-2 inhibitors or oral/topical NSAIDs may be helpful for symptomatic management of flare-ups and chronic arthropathy when corticosteroids are not indicated.” (opens the source at this quote in a new tab)

Use after corticosteroids and associated precautions

“When prednisone is discontinued (or if a flare-up existing for more than 48 h is being considered for treatment), symptomatic treatment may be considered with a non-steroidal anti-inflammatory agent (NSAID). A COX-2 inhibitor can be used instead of a traditional NSAID ( Table 1 ). As with all NSAIDs, GI precautions should prevail. If long-term use of a COX-2 inhibitor is considered, serum liver and kidney function tests should be monitored.” (opens the source at this quote in a new tab)

Back and chest flare-ups

“Consider non-steroidal anti-inflammatory medications (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors (oral or topical) with assiduous gastrointestinal (GI) precautions. Use analgesics, muscle relaxants, and local applications of ice packs, as needed. Avoid narcotic analgesia.” (opens the source at this quote in a new tab)

Celecoxib dosing

“Peds and Adults: 100–200 mg po bid for maintenance, at discretion of M.D.” (opens the source at this quote in a new tab)